A Phase I/IIa study of safety, tolerability, and pharma-cokinetic profiles of TG-2349, a pan-genotypic HCV protease inhibitor, in healthy East Asian and Caucasian subjects, and its antiviral activity in chronic hepatitis C patients
Resource
Hepatology, 58(6), 1388A-1388A
Journal
Hepatology
Journal Volume
58
Journal Issue
6
Pages
-
Date Issued
2013
Date
2013
Author(s)
Tsai, Chen-En
Chang, Li-Wen
Chang, Yu-Ting
Hsu, Chiung-Yuan
Chen, Chih-Ming
Tsai, Cheng-Yuan
Lin, Chu-Chung
King, Chi-Hsin R.
Liu, Chun-Jen
Chen, Ding-Shinn
Hsu, Ming-Chu
SDGs